Ladenburg Thalmann Initiates Coverage on VBI Vaccines Inc(NASDAQ:VBIV). The shares have been rated Buy. The rating by Ladenburg Thalmann was issued on Jul 26, 2016.
VBI Vaccines Inc (VBIV) made into the market gainers list on Fridays trading session with the shares advancing 0.53% or 0.02 points. Due to strong positive momentum, the stock ended at $3.8, which is also near the day’s high of $3.84. The stock began the session at $3.8 and the volume stood at 65,787 shares. The 52-week high of the shares is $11.6 and the 52 week low is $3.4. The company has a current market capitalization of $137 M and it has 3,59,66,581 shares in outstanding.
VBI Vaccines Inc. formerly Paulson Capital Corp. is a biopharmaceutical company. The Company is engaged in the formulation development and delivery of vaccines that expand and enhance vaccine protection. The Company’s eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. The Company has initiated work for manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company’s Lipid Particle Vaccine technology (LPV) is a vaccine formulation technology that enables the thermostabilization of vaccines through a formulation and freeze-drying process. The company has completed proof of concept thermostability studies on a number of vaccine and biologic targets.